De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care. (PubMed, Clin Transplant) - Dec 18, 2025 - "De novo LTV in R+ KTRs appears to be safe and effective compared to VGC. This study suggests antiviral prophylaxis is more likely to be successfully completed with LTV and requires less dose titration. Additionally, LTV appears to be associated with less myelosuppression, permitting higher mycophenolate doses at 12 months and avoiding corrective healthcare resource utilization."
Journal • Retrospective data • Cytomegalovirus Infection • Hematological Disorders • Leukopenia • Neutropenia • Transplantation
|
|
Chris Saddler; David Al-Adra; Didier Mandlebrot; Glen E Leverson; Hanna L Kleiboeker; Jillian L Descourouez; Margaret R Jorgenson; Michael J Scolarici
|